Aspire-Lakewood vs Silo Pharma
ASBP and SILO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASBP and SILO compare
Aspire-Lakewood is the larger company, worth 4.3 times as much as Silo Pharma ($11.6M against $2.7M).
Silo Pharma keeps more of each dollar of sales as profit, with a net margin of −8270% compared with −11314% at Aspire-Lakewood.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASBP | SILO |
|---|---|---|
| Size and price | ||
| Market cap | $11.6M | $2.7M |
| Share price | $8.30 | $1.71 |
| Change, 1 year | 95.8% | −72.4% |
| Change, 5 years | – | −98.8% |
| Beta (5Y) | – | 2.90 |
| Employees | – | 3 |
| StockData Score | ||
| Total score | 2 | 2 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 119× | 50.2× (better) |
| P/B | 1.0× | 0.6× (better) |
| Growth | ||
| Revenue growth (TTM) | – | −25.0% |
| Revenue growth, 5Y average | – | 12.0% |
| Profitability | ||
| Gross margin | −25.0% | −14.8% (better) |
| Operating margin | −7495% (better) | −8250% |
| Net margin | −11314% | −8270% (better) |
| Return on equity | −1032% | −91.2% (better) |
| Financial health | ||
| Interest coverage | −0.8× (better) | −112.0× |
| Current ratio | 7.99 (better) | 5.36 |
| Altman Z-score | −0.10 (better) | −5.17 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 9.0% |
| Held by insiders | 1.4% | 13.8% |
| Insider net buying, 12 months | – | $2.1K |
| Short interest, % of float | – | 1.0% |
Go deeper
- ASBP stock overview
- ASBP income statement
- ASBP valuation and score
- SILO stock overview
- SILO income statement
- SILO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.